TiGenix to acquire Orthomimetics, a developer of collagen biomaterials that support scaffolds for cartilage, meniscus, ligament and tendon repair

By

     
TiGenix, a privately held medical technology company based in Cambridge, the United Kingdom, will issue ~3.7MM shares to purchase all outstanding shares of Orthomimetics, for a transaction value of €16MM (US $23.8MM) on a debt and cash free basis.  
Orthomimetics was founded in 2005 as a spin-out from the University of Cambridge and the Massachusetts Institute of Technology (MIT). Its products are based on a leading collagen biomaterials platform for the production of scaffolds for cartilage, meniscus, ligament and tendon repair.
CambridgeNetwork...  http://ow.ly/CJgz
...

Get access to full posts newsletters, trends, and market reports for only subscribe for $1/day.
Hit the SUBSCRIBE button at the top of the homepage.